South Korea · Delayed Price · Currency is KRW Kainos Medicine Statistics
Total Valuation
Kainos Medicine has a market cap or net worth of KRW 35.56 billion. The enterprise value is 37.38 billion.
| Market Cap | 35.56B |
| Enterprise Value | 37.38B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kainos Medicine has 32.71 million shares outstanding. The number of shares has increased by 12.81% in one year.
| Current Share Class | 32.71M |
| Shares Outstanding | 32.71M |
| Shares Change (YoY) | +12.81% |
| Shares Change (QoQ) | +1.17% |
| Owned by Insiders (%) | 22.70% |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.31 |
| PB Ratio | 16.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 26.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.01.
| Current Ratio | 1.15 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -373.90 |
Financial Efficiency
Return on equity (ROE) is -107.66% and return on invested capital (ROIC) is -60.65%.
| Return on Equity (ROE) | -107.66% |
| Return on Assets (ROA) | -46.49% |
| Return on Invested Capital (ROIC) | -60.65% |
| Return on Capital Employed (ROCE) | -267.48% |
| Weighted Average Cost of Capital (WACC) | 9.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kainos Medicine has paid 3.51 million in taxes.
| Income Tax | 3.51M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.03% in the last 52 weeks. The beta is 0.88, so Kainos Medicine's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | -73.03% |
| 50-Day Moving Average | 1,104.96 |
| 200-Day Moving Average | 1,939.78 |
| Relative Strength Index (RSI) | 50.94 |
| Average Volume (20 Days) | 481,084 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kainos Medicine had revenue of KRW 1.40 billion and -6.33 billion in losses. Loss per share was -192.78.
| Revenue | 1.40B |
| Gross Profit | 338.51M |
| Operating Income | -5.87B |
| Pretax Income | -6.33B |
| Net Income | -6.33B |
| EBITDA | -5.59B |
| EBIT | -5.87B |
| Loss Per Share | -192.78 |
Balance Sheet
The company has 772.92 million in cash and 31.25 million in debt, with a net cash position of 741.66 million or 22.67 per share.
| Cash & Cash Equivalents | 772.92M |
| Total Debt | 31.25M |
| Net Cash | 741.66M |
| Net Cash Per Share | 22.67 |
| Equity (Book Value) | 2.19B |
| Book Value Per Share | -38.13 |
| Working Capital | 300.37M |
Cash Flow
In the last 12 months, operating cash flow was -3.77 billion and capital expenditures -2.12 million, giving a free cash flow of -3.77 billion.
| Operating Cash Flow | -3.77B |
| Capital Expenditures | -2.12M |
| Depreciation & Amortization | 277.99M |
| Net Borrowing | -326.85M |
| Free Cash Flow | -3.77B |
| FCF Per Share | -115.21 |
Margins
| Gross Margin | 24.10% |
| Operating Margin | -417.83% |
| Pretax Margin | -450.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kainos Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.81% |
| Shareholder Yield | -12.81% |
| Earnings Yield | -17.81% |
| FCF Yield | -10.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 24, 2022. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jun 24, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Kainos Medicine has an Altman Z-Score of -40.06 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -40.06 |
| Piotroski F-Score | 2 |